NCT00401739View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

CSL360

Weekly IV Infusion. Dose escalation study.

Trial Locations (6)

2145

Westmead Hospital, Westmead

3002

Peter MacCallum Cancer Institute, Melbourne

3052

Royal Melbourne Hospital, Melbourne

4029

Royal Brisbane and Women's Hospital, Brisbane

4102

Princess Alexandra Hospital, Woolloongabba

5000

Institute of Medical & Veterinary Science, Adelaide

All Listed Sponsors
lead

CSL Limited

INDUSTRY

NCT00401739 - Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter